Enrico Mini
Enrico Mini
Verified email at
Cited by
Cited by
Natural compounds for cancer treatment and prevention
S Nobili, D Lippi, E Witort, M Donnini, L Bausi, E Mini, S Capaccioli
Pharmacological research 59 (6), 365-378, 2009
Cellular pharmacology of gemcitabine
E Mini, S Nobili, B Caciagli, I Landini, T Mazzei
Annals of oncology 17, v7-v12, 2006
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3
E Van Cutsem, R Labianca, G Bodoky, C Barone, E Aranda, B Nordlinger, ...
Journal of Clinical Oncology 27 (19), 3117-3125, 2009
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies
S Nobili, E Mini, I Landini, C Gabbiani, A Casini, L Messori
Medicinal research reviews 30 (3), 550-580, 2010
Pharmacokinetic drug interactions of macrolides
P Periti, T Mazzei, E Mini, A Novelli
Clinical pharmacokinetics 23 (2), 106-131, 1992
Pharmacological strategies for overcoming multidrug resistance
S Nobili, I Landini, B Giglioni, E Mini
Current drug targets 7 (7), 861-879, 2006
Gold (III) complexes as potential antitumor agents: solution chemistry and cytotoxic properties of some selected gold (III) compounds
L Messori, F Abbate, G Marcon, P Orioli, M Fontani, E Mini, T Mazzei, ...
Journal of medicinal chemistry 43 (19), 3541-3548, 2000
Structure, expression, and regulation of protein kinases involved in the phosphorylation of ribosomal protein S6
RL Erikson
The Journal of biological chemistry (Print) 266 (10), 6007-6010, 1991
Gold (III) complexes with bipyridyl ligands: solution chemistry, cytotoxicity, and DNA binding properties
G Marcon, S Carotti, M Coronnello, L Messori, E Mini, P Orioli, T Mazzei, ...
Journal of Medicinal Chemistry 45 (8), 1672-1677, 2002
Gold (III) compounds as anticancer agents: Relevance of gold–protein interactions for their mechanism of action
A Casini, C Hartinger, C Gabbiani, E Mini, PJ Dyson, BK Keppler, ...
Journal of inorganic biochemistry 102 (3), 564-575, 2008
A novel inward‐rectifying K+ current with a cell‐cycle dependence governs the resting potential of mammalian neuroblastoma cells.
A Arcangeli, L Bianchi, A Becchetti, L Faravelli, M Coronnello, E Mini, ...
The Journal of Physiology 489 (2), 455-471, 1995
High-Resolution Melting Analysis for Rapid Detection of KRAS, BRAF, and PIK3CA Gene Mutations in Colorectal Cancer
L Simi, N Pratesi, M Vignoli, R Sestini, F Cianchi, R Valanzano, S Nobili, ...
American journal of clinical pathology 130 (2), 247-253, 2008
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial
J Taieb, J Tabernero, E Mini, F Subtil, G Folprecht, JL Van Laethem, ...
The Lancet Oncology 15 (8), 862-873, 2014
Chemistry and mode of action of macrolides
T Mazzei, E Mini, A Novelli, P Periti
Journal of Antimicrobial Chemotherapy 31 (suppl_C), 1-9, 1993
Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum
S Capaccioli, G Dipasquale, E Mini, T Mazzei, A Quattrone
Biochemical and biophysical research communications 197 (2), 818-825, 1993
Structural and solution chemistry, antiproliferative effects, and DNA and protein binding properties of a series of dinuclear gold (III) compounds with bipyridyl ligands
A Casini, MA Cinellu, G Minghetti, C Gabbiani, M Coronnello, E Mini, ...
Journal of Medicinal Chemistry 49 (18), 5524-5531, 2006
Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines.
DE McCloskey, JJ McGuire, CA Russell, BG Rowan, JR Bertino, ...
Journal of Biological Chemistry 266 (10), 6181-6187, 1991
Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer
J Taieb, K Le Malicot, Q Shi, F Penault-Llorca, O Bouché, J Tabernero, ...
JNCI: Journal of the National Cancer Institute 109 (5), 2017
Adverse effects of macrolide antibacterials
P Periti, T Mazzei, E Mini, A Novelli
Drug safety 9 (5), 346-364, 1993
Effect of methylenetetrahydrofolate reductase 677C→ T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients
G Toffoli, A Russo, F Innocenti, G Corona, S Tumolo, F Sartor, E Mini, ...
International journal of cancer 103 (3), 294-299, 2003
The system can't perform the operation now. Try again later.
Articles 1–20